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Abstract 
BACKGROUND: 
To quantify the association between anticholinergic drug use (burden or load) and cognitive function (MMSE), blood 
pressure and the presence of anticholinergic side effects.  
METHODS:  
The medical records of 182 aged care home residents in the Perth metropolitan area, Western Australia were 
reviewed retrospectively to obtain demographic data, past and current medical problems, history of use of agents 
with anticholinergic effects and the following medication-related problems: cognitive impairment (as determined by 
Mini Mental State Examination {MMSE} score), blood pressure elevation and the presence of anticholinergic side 
effects. Anticholinergic load was calculated, and the relationship between the anticholinergic load and the presence 
of anticholinergic side effects was assessed using stepwise multiple regression and multiple logistic regression 
analysis. 
RESULTS:  
Increasing anticholinergic load was associated with the presence of peripheral anticholinergic side effects including 
hypertension (AOR=1.53), dry mouth (AOR=1.38), dry eyes (AOR=1.30), constipation (AOR=1.24) and urinary 
hesitancy (AOR=1.21) (all p values ≤0.05). The anticholinergic load was not associated with blurred vision (p=0.084) 
and Mini Mental State Examination score decline (p=0.142). 
CONCLUSIONS: 
The anticholinergic load was associated with statistically significantly increased risk of peripheral anticholinergic 
adverse effects in older aged care residents, however not with cognitive decline.   Australasian Medical Journal 2009, 1, 3, 1-26 
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Introduction 
 
Older people have an increased likelihood of illness and as a result receive a disproportionate amount of 
over-the–counter and prescribed medications.
1 In the USA people over 65 used 30% of prescription and 
40% of over-the–counter medicines, despite making up only 13% of population.
1 In the UK, the old aged 
comprised only 18% of population but consumed 45% of all prescription drugs. Some of these medications 
are prescribed inappropriately and without attention to side effects. Elderly people living in aged care 
facilities are even more likely to receive medications and to be exposed to side effects.
1 Blazer et al 
reported in one year, 97% of elderly patients in aged care facilities obtained a prescribed drug, compared 
with 71% of patients living in the community.
2 Longitudinal data from Australia (1981 through 2002) has 
shown the rate of adverse drug events to be on the rise.
3 The largest increase manifested in those persons 
aged over 80 years; a tenfold increase in men and a sevenfold increase in women.
3  
Moreover, older people frequently have low health expectations and are less likely to recognize 
medication adverse effects. In addition, patients with cognitive decline have difficulties in communication 
of their discomfort. Consequently, those living in aged care homes may rely on carers to prompt the 
physician to realize possible adverse drug events. This is particularly the case for anticholinergic side 
effects, which are among the most common drug-related problems experienced by elderly people living in 
nursing homes.
4, 5 According to the Beer et al criteria
6 aimed at identifying drugs deemed inappropriate 
for use in the elderly (aged ≥65 years), drugs with anticholinergic properties are frequently regarded as 
examples of inappropriate medications to prescribe because they constitute an increased risk for many   Australasian Medical Journal 2009, 1, 3, 1-26 
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adverse drug effects, such as dry mouth, constipation, urinary retention, visual impairment, falls, 
confusion, drowsiness, delirium and cognitive decline.
7 There are many common anticholinergic side 
effects which may contribute to significant clinical problems. For instance, dry mouth can lead to speech 
difficulties, dental decay or trouble with dentures.
2, 8 Chewing and swallowing may become painful and 
can result in refusing of solid food. Pupillary dilation and the inability to accommodate will affect near 
vision, thereby increasing the risk of accidents, including falls and may worsen narrow angle glaucoma in 
predisposed patients. In the case of constipation, anticholinergic effect may lead to stomatitis, paralytic 
ileus or faecal impaction.
2, 8 Drug-induced increases in heart rate may precipitate angina symptoms and 
inhibition of sweating may cause life-threatening hyperthermia. Urinary retention can cause urinary tract 
infection, a common cause of delirium. Men with benign prostatic hypertrophy are at high increased risk 
of acute urinary retention from an anticholinergic side effect.
2, 8 
Anticholinergic medications are the most common cause of drug-induced delirium. In patients with 
dementia, anticholinergic drugs can inhibit cognitive performance and compromise the beneficial effect of 
cholinergic enhancers used to treat cognitive impairment.
9, 10 Additionally, polypharmacy and the 
concurrent chronic use of multiple drugs are a reality for older patients.
11 Thus, anticholinergic adverse 
effects may result  from the cumulative anticholinergic burden of multiple drugs. Consequently, the 
combination of drugs can contribute clinically important adverse drug reactions, even if the individual 
drugs do not cause obvious side effects.
12 
A number of studies have reported on the common use of anticholinergic medications in elderly people. 
Blazer et al
2 reported that during one year, nearly 60% of aged care facility residents had received drugs 
with anticholinergic activity, compared with 23% of elderly people living in the community. The 
Established Population of Epidemiologic Studies of the elderly study, a US prospective cohort study,   Australasian Medical Journal 2009, 1, 3, 1-26 
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showed that chlorpheniramine and diphenhydramine were among the 10 most commonly identified 
inappropriate drugs used in elderly patients.
13 A prospective cohort study in 532 patients with intact 
cognitive function conducted in the primary care clinics at the Veterans Affairs Medical Center (VAMC), 
Iowa City, demonstrated that 27.1% of patients used at least one medication with anticholinergic action.
14 
In a longitudinal study in 9294 community-based elderly patients in France
15, 6.4% of patients used drugs 
with anticholinergic properties. In a retrospective cohort study involving 765,423 elderly patients covered 
by a pharmaceutical benefit manager and who filed ≥ 1 prescription drug claim in 1999 in US
16, 
amitriptyline and doxepin were reported to account for almost one quarter of all inappropriate drugs 
prescribed. 
In addition, there are several studies that demonstrated the association between the use of 
anticholinergic drugs (anticholinergic load) and anticholinergic side effects. A prospective cohort study in 
364 elderly patients in Italy
17 found that anticholinergic drug use was associated with impaired physical 
performance and muscle strength, irrespective of potential confounders and that this association 
correlated with the increasing number of anticholinergic drugs used. Additionally, a number of other 
studies have reported the association of anticholinergic drug use with cognitive impairment.
12, 18-23 A 
retrospective, medical record review at two urban tertiary care teaching hospitals, found that the most 
common side-effects from anticholinergic medications were decreased secretions, tachycardia, confusion 
and drowsiness. 
24 
To our knowledge, few studies have investigated the association between anticholinergic load and overall 
anticholinergic side-effects. Therefore, identifying the association of anticholinergic load and 
anticholinergic drug-related problems could contribute to the better understanding, assessment, 
prevention and management of anticholinergic side effects in elderly people. This study was therefore   Australasian Medical Journal 2009, 1, 3, 1-26 
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undertaken to quantify the association between the anticholinergic load and medication-related problems 
amongst residents of aged care homes. 
Methods 
 
SETTING 
A retrospective cohort study was conducted at three aged care homes in the Perth metropolitan area, 
Western Australia. It was undertaken as a quality use of medicines (QUM) activity as part of the residents’ 
annual medication management reviews (MMR), which are undertaken by an accredited pharmacist and 
funded by the Australian Government. 
PARTICIPANTS 
Participants in the study were aged care home residents aged over 65 years old. The participants were 
recruited through the medication management review program conducted in their aged care homes as 
part of standard care. All residents in aged care homes in Australia are entitled to an annual medication 
management review. As part of the medication management review process, the review pharmacists are 
required to undertake a range of quality use of medicines (QUM) activities and this study was undertaken 
as one of these activities. Aged care home residents at the time of their admission are required to provide 
written consent for medication management reviews to be undertaken. Therefore, individual patient 
consent for the study was not required. This study was approved by the Curtin University of Technology 
Human Research Ethics Committee and Ethics Committees of the aged care homes. 
   Australasian Medical Journal 2009, 1, 3, 1-26 
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DATA COLLECTION 
All study data were collected by the primary researcher via patient interviews and review of patients’ 
medical records. The data was collected using a standardized data collection form and included patient 
demographics, current and past medical conditions (co-morbidities), medication history, in particular the 
use of drugs with anticholinergic activity, and the presence of specific medication-related problems, 
namely cognitive impairment (as determined by the Mini Mental State Examination score), high blood 
pressure and the presence of other potential anticholinergic side effects. Patient interviews were carried 
out to determine the presence of symptoms consistent with anticholinergic adverse effects.  
 Anticholinergic drugs were categorized into two groups; anticholinergic drugs and drugs with 
anticholinergic effects.  The lists of anticholinergic medications used in this study are adapted from several 
studies.
5, 12, 18, 19, 22, 24-28 Cognitive performance was assessed using the Mini Mental State Examination.
29 
The Mini Mental State Examination score is used to ascertain the severity of the patient’s cognitive 
impairment by assessing orientation, registration, attention, calculation, recall, and praxis. Possible scores 
range from 0 to 30, with lower scores representing greater cognitive impairment.  
The following five anticholinergic symptoms modified from Jose Ness et al
14 were used as the 
anticholinergic side effects; dry mouth, dry eyes, blurred vision, constipation and urinary hesitancy. The 
presence of these side effects was evaluated based on the patient’s past medical history, use of 
medications potentially used to treat anticholinergic symptoms including artificial tears, stool softeners, 
laxatives, alpha-blockers, finasteride and saw palmetto; and findings from the patient interviews.   Australasian Medical Journal 2009, 1, 3, 1-26 
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The anticholinergic load was derived from the total number of anticholinergic medications taken by the 
patient. The prevalence of cognitive impairment, hypertension and anticholinergic adverse events was 
evaluated based on the patient’s anticholinergic load taking into consideration any co-morbidities.  
STATISTICAL ANALYSIS 
Descriptive statistics were complied in the sample according to age, gender, co-morbidities, the use and 
the number of medications  with anticholinergic properties (anticholinergic load), anticholinergic side 
effects, and the Mini Mental State Examination scores. The association between anticholinergic load and 
cognitive impairment (the Mini Mental State Examination scores) was assessed using stepwise multiple 
regression analysis adjusted for all related co-morbidities. To assess the extent to which the presence of 
peripheral anticholinergic side effects was related to the anticholinergic load, a multiple logistic regression 
model was created to predict such a relationship taking into account the anticholinergic load and all 
identified co-morbidities related to each anticholinergic side effect. A p value ≤ 0.05 was considered 
statistically significant. All analyses were conducted using SPSS program version 15.0.  
Results 
 
A total of 182 patients’ medical records were reviewed for the study. Of these, seven patients were 
excluded as they were found to be less than 65 years old. Therefore, 175 patients’ data were included in 
the data analysis. For the cognitive function, data on the Mini Mental State Examination scores was 
obtained from 161 patients; in 12 of the remaining 14 patients Mini Mental State Examination was not 
able to be performed due to severe cognitive impairment and, whilst the other two patients declined to   Australasian Medical Journal 2009, 1, 3, 1-26 
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be tested. These 14 patients consisted of three males and 11 females who had a mean (SD) anticholinergic 
load 3.2 (1.8). 
The distribution of age, sex, marital status, the use and number of anticholinergic medications, the Mini 
Mental State Examination scores, anticholinergic side effects, and co-morbidities are summarized in Table 
1. The mean age was 87.0 (8.0) years and 71.4% of the subjects were women. Of the 175 patients, 89.6% 
were receiving at least one anticholinergic medication; with the mean number of medications being of 2.9 
(1.9). The mean Mini Mental State Examination score of the 161 evaluable patients was 20.2 (7.0). The 
three most common potential anticholinergic side effects identified were hypertension (66.3%), 
constipation (63.4%) and blurred vision (40.0%). The most frequently prescribed medications with 
anticholinergic activity were temazepam (35.4%), frusemide (31.4%) and loperamide (14.3%). The most 
common co-morbidities were hypertension (66.3%), dementia (64.6%) and psychological/behavioral 
disorders (58.3%). 
 The association between the anticholinergic load (the number of anticholinergic medication used) and cognitive 
impairment was assessed using the stepwise multiple logistic regression (Table 2) after adjusting for age and the 
following co-morbidities: urinary tract infection, hypothyroidism, renal failure, thiamine deficiency, vitamin B12 
deficiency, diabetes mellitus, dementia, psychotic disorders and Korsakoff’s syndrome. Among all co-morbidities, 
only dementia (p=0.000) and psychotic disorders (p=0.021) were included in the regression model as they had a 
significant negative impact on the Mini Mental State Examination scores. There was an inverse correlation 
between anticholinergic load and Mini Mental State Examination scores but this was not statistically significant 
(beta = -0.114, p=0.142) after adjusting for these co-morbidities. 
Table 3 presents the factors significantly associated with each of the targeted anticholinergic side effects. 
The effect of age and the various co-morbidities (diabetes mellitus, chronic renal failure, ischaemic heart   Australasian Medical Journal 2009, 1, 3, 1-26 
 
26 
disease, hypercholesterolemia and hypothyroidism) and anticholinergic load on hypertension was 
assessed using the multiple logistic regression. From this analysis, hypercholesterolemia (p=0.005) and the 
anticholinergic load (p=0.000) were the only variables that had a significant impact on increasing the 
likelihood of patients experiencing hypertension. Each increase in the number of anticholinergic 
medications prescribed was associated with a 1.53-fold increase in the likelihood of hypertension 
(Adjusted Odds Ratio [AOR] = 1.53, 95% CI: 1.24-1.88, p= 0.000).  
 
For dry mouth, the related factors included in the analysis were diabetes mellitus, anaemia, dementia, 
stroke, psychological disorders, postmenopausal status and age. After adjusting for all these factors, only 
the anticholinergic load demonstrated a significant impact on the likelihood on dry mouth. The increase in 
the number of anticholinergic medications accounted for an increased risk in the presence of dry mouth. 
(AOR = 1.38, 95%CI: 1.16-1.65, p= 0.000).  
 
Similar to dry mouth, after adjusting other contributing factors (postmenopausal status, diabetes mellitus, 
stroke, asthma, glaucoma and age), only the anticholinergic load had a positive association with dry eyes. 
For each increase in the number of anticholinergic medications received there was an associated 1.30-fold 
increase in the likelihood of dry eyes (AOR = 1.30, 95%CI: 1.08-1.56, p= 0.007).  
 
A multiple logistic regression analysis failed to show the anticholinergic load to be a predictive factor for 
blurred vision (p=0.084). After adjusting all related co-morbidities (macular degeneration, diabetes 
mellitus, cataract, stroke and glaucoma) and age, the number of anticholinergic medications did not have 
a significant impact on blurred vision, whereas, the presence of glaucoma (p= 0.000) and macular 
degeneration (p=0.005) increased the likelihood of blurred vision significantly. The anticholinergic load did   Australasian Medical Journal 2009, 1, 3, 1-26 
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not have an impact on likelihood of patients suffering from glaucoma after adjusting for age, 
hypertension, diabetes mellitus and the use of corticosteroids (p = 0.702).  
 
In terms of  constipation, after adjustment for other possible causes of constipation including 
hypothyroidism, diabetes mellitus, psychological disorders, stroke and age, the only significant predictors 
of constipation were the anticholinergic load (p=0.031) and psychological disorders (p=0.025). For each 
increase in the number of anticholinergic medications received there was an associated 1.24-fold increase 
in the likelihood of constipation (AOR 1.2495%CI: 1.02-1.50, p= 0.031).  
 
Lastly, urinary hesitancy was affected by the presence of benign prostatic hyperplasia (p=0.020) prostate 
cancer (p=0.045) anticholinergic load (p=0.050) after adjustment of all possible risk factors (benign 
prostatic hyperplasia, prostate cancer, diabetes mellitus, chronic renal failure, urinary incontinence, 
recurrent urinary tract infection and age). For each increase in the number of anticholinergic medications 
received there was an associated 1.21-fold increase in the likelihood of urinary hesitancy (AOR = 1.21. 95% 
CI: 1.00-1.45, p= 0.050).  
Discussion 
 
The results of this study demonstrated that the anticholinergic load measured by the number of 
anticholinergic drugs received was significantly associated with the presence of all peripheral 
anticholinergic side effects with the exception of blurred vision, suggesting that these side effects are 
clinically significant. This association was not attributable to co-morbidities or age. In the case of blurred   Australasian Medical Journal 2009, 1, 3, 1-26 
 
26 
vision, its occurrence was correlated with glaucoma and macular degeneration, but not anticholinergic 
load. Given that anticholinergic agents should be used with caution in patients with glaucoma a sub-
analysis was undertaken to determine if there was a relationship between anticholinergic load and 
glaucoma, and hence anticholinergic load may be secondary contributor to blurred vision. This was not 
found to be the case, which validated the initial finding that anticholinergic load was not associated with 
blurred vision. 
Whilst anticholinergic load was found to be inversely correlated with decline in the Mini Mental State 
Examination scores, the association was not statistically significant (p=0.142). The lack of a significant 
association between the anticholinerigic load and the Mini Mental State Examination score decline is of 
particular interest because several previous experimental and epidemiological studies indicated that the 
use of medications with anticholinergic activity were associated with changes on several measures of 
cognitive function (including the Mini Mental State Examination).
12, 19-23, 30-34 Several studies have also 
shown that the use of anticholinergic drugs was a common risk factor for delirium.
9, 18, 28, 35-38 One study 
showed that even a low anticholinergic serum level can cause mild but measurable cognitive impairment 
in the presurgical elderly
39 and memory deficit in geriatric depressed subjects. Mulsant et al
20 measured 
serum anticholinergic activity in a sample of 201 elderly subjects living in the community and examined 
the relationship between serum anticholinergic activity and cognitive performance. They found that 
subjects with serum anticholinergic activity at or above the sample’s 90
th percentile point were 
significantly more likely than subjects with undetectable serum anticholinergic activity to show a low Mini 
Mental State Examination score. However, all the studies mentioned above used serum anticholinergic 
activity as the anticholinergic load. Serum anticholinergic activity, despite a number of limitations, is still 
considered the current gold standard in quantifying the anticholinergic burden.
40   Australasian Medical Journal 2009, 1, 3, 1-26 
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The result of this study, that is the lack of a negative effect of anticholinergic load on Mini Mental State 
Examination scores, is however supported by several other studies. Remillard et al
41 reported that there 
was no association between serum anticholinergic activity and the Mini Mental State Examination score 
decline and Audrey-verbal learning test in a small group of subjects. Tracy et al
42 examined the 
anticholinergic burden imposed by clozapine and risperidone, and found that the Mini Mental State 
Examination scores were not related to the anticholinergic level, although the anticholinergic levels were 
significantly higher for clozapine group than risperidone group (p<0.001). Seifert et al
43 also reported that 
no statistically significant correlation could be found between the presence of confusion and the amount 
of anticholinergic administered. Again, these two studies used a small sample size and focused on 
antidepressants and antipsychotics only. Another study revealed a weak association between 
anticholinergic burden with physical function and cognition when the anticholinergic burden was 
calculated using the number of anticholinergic drugs rather than the standardized dose of the drug and 
principle of maximum effect (dose and frequency of use).
34  
The finding of an association between the use of anticholinergic drugs and peripheral anticholinergic side 
effects but not central anticholinergic side effects could represent a real difference in the sensitivity of 
central and peripheral nervous system or could result from the heterogenicity of subject population.
44 
Furthermore, the more pronounced association between the anticholinergic load and peripheral 
anticholinergic side effects than central anticholinergic side effects may be due to the fact that peripheral 
side effects are more physical than central side effects, and therefore might be easier to diagnose and 
more sensitive to manifest according to the anticholinergic load.
45  
In terms of peripheral side effects, the results were consistent to several studies. Monane et al
46 
measured the relationship between the use of anticholinergic drugs and bowel dysfunction in nursing   Australasian Medical Journal 2009, 1, 3, 1-26 
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home patients and found a strong association in institutionalized elderly between the use of specific 
anticholinergic medications and constipation as reflected in the increased use of laxatives. The result of 
dry mouth and the anticholinergic load was congruent with Thomson et al’s
47 study showing the higher 
prevalence of xerostomia in patients taking anticholinergic medications. 
In a recent study by Rudolph et al
48, the Anticholinergic Risk Scale, a ranked categorical list of commonly 
prescribed medications with anticholinergic potential was developed. The study then evaluated 
Anticholinergic Risk Scale scores as the risk factor of anticholinergic adverse effects in two cohorts of 
patients (a geriatric evaluation and management (GEM) cohort and in primary care cohort). Higher 
Anticholinergic Risk Scale scores were linked to an increased risk for central anticholinergic adverse effects 
in GEM group and peripheral anticholinergic side effects in both groups.  
Another interesting finding of this study was the common use drugs with anticholinergic activity amongst 
residents of aged-care homes (89.6%) which is consistent with the findings of previously published 
studies.
13-16 This finding supports the growing concern about the prescribing of drugs with anticholinergic 
activity deemed as an inappropriate in this age group according to the Beer et al criteria.
6 Concerning was 
the fact that the majority of medications with anticholinergic activity being consumed by the patients in 
this study were available only on prescription. Therefore, it was assumed a physician prescribed the 
medications thereby suggesting the need of education program for prescribers aimed at producing a 
substantial reduction in the use of these medications.
49 The high frequency of benzodiazepine use, in this 
case, temazepam, can increase the risk of delirium and falls.
36 Therefore, healthcare providers should 
offer other options to such patients (i.e. nonphamacological) rather than prescribing the medication as 
the first choice.
50 Kay et al
12 suggested that prescribers should review patient’s medical history, total 
anticholinergic burden and level of cognitive impairment prior to prescribing anticholinergic medications.   Australasian Medical Journal 2009, 1, 3, 1-26 
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The study has a number of limitations. Firstly, the generalizability beyond the elderly living in aged-care 
facilities is limited. Secondly, the use of number of anticholinergic drugs as the anticholinergic load is an 
estimate. It is possible that the accuracy of the anticholinergic load could be further improved by using the 
more intensive methods like serum anticholinergic activity
40 or drug burden index
34 which accounted for 
the dose and frequency of use or the anticholinergic drug scale
40 which has been shown to relate to serum 
anticholinergic activity. In addition, it would have been useful if the duration of therapy could have been 
incorporated into the anticholinergic load, which would have allowed evaluation of the duration-response 
relationship between the use of anticholinergic drugs and overall side effects. However, accurate data on 
the duration of therapy was not available in this study. Nevertheless, the anticholinergic load calculated 
by the relatively straightforward method used in this study still demonstrated an effect on peripheral 
anticholinergic side effects that was independent of the patients’ co-morbidities. Thirdly, despite the use 
of information from several published literature sources, the identification of all possible medications with 
anticholinergic activity was not possible. This deficiency may have lead to the underestimation of the 
anticholinergic load. Fourthly, the use of the Mini Mental State Examination as the measurement of 
cognitive performance may not able to detect mild or transient impairment. This test was designed 
primarily to establish the sort of marked cognitive decline that accounts for frank delirium or dementia.
29 
However, the use of logistic regression analysis in which adjustment for all related co-morbidities was 
undertaken enhances the confidence with which the relationship between the anticholinergic load and 
anticholinergic side effects can be reported. 
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Conclusions 
We have established an association between the anticholinergic load, as defined by the number of 
anticholinergic drugs a patient is taking, and occurrence of peripheral anticholinergic side effects with the 
exception of blurred vision amongst residents of age-care home. These results highlight the need for 
prescribers and other health care providers to aware of wide range of medications with anticholinergic 
activity, and the need to assess anticholinergic load when elderly patients develop common problems 
such as hypertension, constipation and dry eyes.  However, further studies involving larger numbers of 
elderly subjects are required to verify whether the number of medications with anticholinergic activity 
which a person is receiving is a sufficiently sensitive indicator of anticholinergic load. 
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Tables 
 
Table 1. Baseline demographic and clinical characteristic of study participants (N = 175) 
Characteristic  Number of Patients  Value 
Age (years)       
  Mean (SD)  175  87.0 (8.0) 
  Median (range)  176  89.0 (65-103) 
Gender       
  Male  50  28.6% 
  Female  125  71.4% 
Anticholinergic medication use       
  No  20  11.4 
  Yes  155  89.6 
No. of anticholinergic medications       
  Mean (SD)  175  2.9 (1.9) 
 Median (range)  175  3.0 (0-8) 
Level of anticholinergic medication use (no. of 
medications prescribed)     
  0-3  115  65.8% 
  4-6  54  30.8% 
  >6  6  3.4% 
MMSE scores       
  Mean (SD)  161  20.2 (7.0) 
  Median (range)  161  21.0 (1-30)   Australasian Medical Journal 2009, 1, 3, 1-26 
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 No. of anticholinergic side effects       
  Mean (SD)  175  2.5 (1.4) 
 Median (range)  175  2.0 (0-6) 
  Hypertension  116  66.3% 
  Dry mouth  55  31.4% 
  Dry eye  40  22.9% 
  Blurred vision  70  40.0% 
  Constipation  111  63.4% 
  Urinary hesitancy  45  25.7% 
Most common anticholinergic medications 
prescribed       
 Temazepam  62  35.4% 
 Frusemide  55  31.4% 
 Loperamide  25  14.3% 
 Metoprolol  24  13.7% 
 Paracetamol/codeine  21  12% 
 Digoxin  17  9.7% 
 Oxazepam  17  9.7% 
Most common co-morbidities       
 Hypertension  116  66.3% 
 Dementia  113  64.6% 
 Psychological/behavioral disorder  102  58.3% 
 Urinary Incontinence  78  44.6% 
 Osteoarthritis  76  43.4% 
Abbreviation: MMSE, Mini-Mental State Examination   Australasian Medical Journal 2009, 1, 3, 1-26 
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Table 2. Stepwise multiple logistic regression analysis of variables associated with cognitive impairment (MMSE 
scores) 
 
  Standardized 
coefficients () 
p value 
Dementia  -.440  0.000 
Psychotic disorder/behavioral 
disorder 
-.178  0.021 
Anticholinergic load  -.114  0.142 
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Table 3. Multiple logistic regression analysis of variables associated with anticholinergic side effects 
 
  AOR*  95.0% CI  p value 
Hypertension       
   Hypercholesterolemia  4.05  1.54-10.65  0.005 
   Anticholinergic load  1.53  1.24-1.88  0.000 
Dry mouth       
   Anticholinergic load  1.38  1.16-1.65  0.000 
Dry eye       
   Anticholinergic load  1.30  1.08-1.56  0.007 
Blurred vision       
  Macular degeneration  9.56  1.96-46.77  0.005 
  Glaucoma  40.86  5.28-316.16  0.000 
Glaucoma       
  Hypertension  5.24  1.17-23.39  0.030 
Constipation       
   Psychological disorder   2.18  1.10-4.30  0.025 
   Anticholinergic load  1.24  1.02-1.50  0.031 
Urinary hesitancy       
   Benign prostatic hyperplasia  14.76  1.53-142.52  0.020 
   Prostate cancer  10.40  1.06-102.12  0.045 
   Anticholinergic load  1.21  1.00-1.45  0.050 
 
* AOR = Adjusted Odds Ratio 